Systemic lupus erythematosus treatment: Positive clinical results
The British pharmaceutical GlaxoSmithKline (GSK) and U.S. Human Genome Sciences (HGS) announced on Monday positive clinical results for a second study of treatment against systemic lupus erythematosus, a chronic inflammatory disease.
The study lasts for 76 weeks and involves 819 patients from 136 locations and 19 countries, which were administered different doses of Benlysta (belimumab) and the standard treatment against the disease, or a placebo and standard therapy.
A significant improvement was found in 43.2% of patients who received 10 mg/kg belimumab and the standard treatment against 33.8% who received placebo and standard therapy.
A first positive study was published in July.
According to the two groups, no new treatments against lupus has been launched on the market for over 50 years.
Systemic lupus erythematosus, which affects about 5 million people worldwide including 1.5 million in the United States, is expressed most frequently in joint pain, skin lesions, facial and kidney damage, more or less severe, and can reach the nervous system and blood.
It is an autoimmune disease. The body attacks itself as if there were foreign elements. Current available treatments (corticosteroids, immunosuppressants) have palliative effects only.
90% of patients with lupus are women under 45 years.
Definition: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Recommended articles:
Cancer: Fight against malignant melanoma
On the trail of a vaccine against brain cancer
Asthma: do follow your treatment!
Most recent in the category Deseases:
- How to Avoid Allergies
- Know about Various Ear Diseases
- COPD or chronic obstructive pulmonary disease
- Myopathy: The promise of pharmacogenetics
- A supergonococci resistant to all common antibiotics
- E.coli: Undercooked meat is the main source
- Malaria: A promising discovery
- Alzheimer's: The real signals for a correct diagnosis
Last comments
Most read - Deseases
- E.coli: Undercooked meat is the main source
- An ultra-resistant to antibiotics bacteria threatens to spread
- A patient with anemia cured by gene therapy
- Hope for Fragile X syndrome
- The cockroaches are perhaps the source of future antibiotics
- Myopathy: The promise of pharmacogenetics
- Chariots of death
- Diagnosing Parkinson by examining the colon
- COPD or chronic obstructive pulmonary disease
- Malaria: The gorillas infected humans
Top rated - Deseases
- How to Avoid Allergies
- Diagnosing Parkinson by examining the colon
- End of pandemic influenza A (H1N1)
- An ultra-resistant to antibiotics bacteria threatens to spread
- The cockroaches are perhaps the source of future antibiotics
- A patient with anemia cured by gene therapy
- Malaria: The gorillas infected humans
- Hope for Fragile X syndrome
- Know about Various Ear Diseases
- Chariots of death
No comments. Be the first to comment the article!